89892-21-7

Usage

Uses

Used in Pharmaceutical Research:
6-Bromoquinazoline is used as a reagent for structure-based design of biaryl mannoside fimH inhibitors. These inhibitors are specifically designed for the treatment of urinary infections caused by bacterial pathogens, such as Escherichia coli, which express type 1 fimbriae. 6-Bromoquinazoline plays a crucial role in the development of novel therapeutic agents targeting the fimH receptor, thereby inhibiting bacterial adhesion and colonization in the urinary tract.

InChI:InChI=1/C8H5BrN2/c9-7-1-2-8-6(3-7)4-10-5-11-8/h1-5H

Upstream product

• 253-82-7 quinazoline 

Downstream Products

• 1373346-94-1 4-(quinazolin-6-yl)phenyl α-D-mannopyranoside 
• 1375301-92-0 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazoline 
• 1416455-36-1 6-(2-fluoro-4-methyl-5-((2,2,2-trifluoroethyl)thio)phenyl)quinazoline 
• 1312448-28-4 N-(2-chloro-5-(quinazolin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 1093818-79-1 N-(2-chloro-5-(quinazolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 32084-59-6 6-bromoquinazolin-4(3H)-one 

Relevant academic research and scientific papers

USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS

The invention relates to methods of using the compounds of the invention, including trifluoromethyl substituted benzamide compounds and salts thereof, as well as pharmaceutical compositions comprising the same, in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders. The invention also relates to modulating the activity of an Eph receptor in a cell, stimulating neural regeneration, and reversing neuronal degeneration, by administering a compound of the invention to a cell or subject in an effective amount.

Trifluoromethyl substituted benzamides as kinase inhibitors

The invention relates to trifluoromethyl substituted benzamide compounds of the formula I, pharmaceuticals comprising these compounds, their use as or for the manufacture of pharmaceuticals, particularly as inhibitors of protein kinases, especially of ephrin receptor kinases, and/or the treatment of a condition, disorder or disease state mediated by a protein kinase activity and/or a proliferative disease, methods of treatment comprising administering the compounds, especially of therapeutic and prophylactic treatment, methods for the manufacture of the compounds and novel intermediates and partial steps for their synthesis.